Clinical Trial Update: Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating regorafenib in metastatic colorectal cancer after progression on standard therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Colorectal Neoplasms

Drugs mentioned

• Regorafenib (regorafenib)

Snippet

Sponsor: Bayer | Conditions: Colorectal Neoplasms | Phase 3 | Status: COMPLETED